Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mature dendritic cell vaccine Clear all
Not listed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00017355
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
filgrastim, therapeutic autologous dendritic cells
Biological
Lead sponsor
Baylor Health Care System
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Results available

Dendritic Cell Vaccination in Patients With Advanced Melanoma

NCT03092453
View directory record Official record
Conditions
Melanoma
Interventions
Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab
Biological · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 28, 2026, 6:09 PM EDT
Not yet recruiting Phase 2 Interventional

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

NCT07634094
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure
Drug · Biological · Procedure
Lead sponsor
Kalinski, Pawel, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma

NCT00683670
View directory record Official record
Conditions
Melanoma
Interventions
cyclophosphamide, Mature dendritic cell vaccine
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 2 Interventional Results available

DC Migration Study for Newly-Diagnosed GBM

NCT02366728
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme
Interventions
Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 111In-labeled DCs, Temozolomide, Saline, Basiliximab
Biological · Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

DC Vaccine in Pancreatic Cancer

NCT03592888
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
mDC3/8-KRAS Vaccine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Phase 1 Interventional

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

NCT01216436
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Vaccination with RNA-transfected mature autologous DC
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Phase 1 Interventional Results available

DC Vaccine in Colorectal Cancer

NCT03730948
View directory record Official record
Conditions
Colorectal Cancer
Interventions
DC vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

NCT00510133
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
GRNVAC1
Biological
Lead sponsor
Asterias Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Atlanta, Georgia • Maywood, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

NCT00098917
View directory record Official record
Conditions
Lung Cancer
Interventions
autologous tumor cell vaccine, therapeutic autologous dendritic cells, adjuvant therapy, biological therapy, conventional surgery, surgery, tumor cell derivative vaccine, vaccine therapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2008 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells

NCT00672542
View directory record Official record
Conditions
Metastatic Melanoma, Absence of CNS Metastases
Interventions
Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
Biological
Lead sponsor
Scott Pruitt
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Phase 2 Interventional Results available

Dendritic Cells (DC) Vaccine for Metastatic Melanoma

NCT01042366
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Vaccination
Biological
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Sep 28, 2026, 6:09 PM EDT
Not listed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005992
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA prostate cancer vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients

NCT00478452
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
DC-Ova, DC Ova with Cyclophosphamide
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00390338
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
polarized dendritic cells, non-polarized dendritic cells
Biological
Lead sponsor
Pawel Kalinski
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma

NCT03927222
View directory record Official record
Conditions
Glioblastoma
Interventions
Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td), GM-CSF, 111-Indium-labeling of Cells for in vivo Trafficking Studies
Biological · Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

Immunization Against Tumor Cells in Sezary Syndrome

NCT00099593
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Sezary Syndrome
Interventions
Autologous Dendritic Cell Vaccine
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 28, 2026, 6:09 PM EDT